Nasal delivery of ALS treatment in tiny cell-made sacs delays disease onset in mice
One of the great challenges in treating diseases like amyotrophic lateral sclerosis (ALS) is not necessarily finding a promising drug. It is getting the drug to the right place.
Amyotrophic lateral sclerosis (ALS) remains a challenging disease to treat due to the difficulty in delivering drugs to the brain and spinal cord. However, researchers at the University of Georgia's Regenerative Bioscience Center have discovered a promising new method. By utilizing naturally produced vesicles from neural stem cells, these tiny carriers can help transport drugs across the blood-brain barrier, potentially improving treatment efficacy.
This approach, paired with antisense oligonucleotides (ASOs), has shown encouraging results in mice. The vesicles not only deliver the ASOs more effectively but also have their own therapeutic properties, enhancing the treatment's impact. This innovative method could offer a simpler alternative to spinal taps for drug delivery in ALS patients, with potential applications extending beyond mice models.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
